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EDITORIAL
Percutaneous treatment of mitral regurgitation:
From feasibility to clinical application?
Traitement percutané de l’insufﬁsance mitrale : des études de faisabilité à
l’application clinique ?KEYWORDS
Mitral regurgitation;
Valve repair;
Mitral regurgitation (MR) is the second most frequent valvular disease among referred
patients in Europe [1]. Indications for surgery are well deﬁned in the guidelines for organic
MR, but their application is unsatisfactory in practice [2,3]. Conversely, current uncer-
tainties arising from risk—beneﬁt analysis explain why indications for surgery are morePercutaneous
techniques
MOTS CLÉS
Insufﬁsance mitrale ;
Plastie mitrale ;
Interventions
percutanées
restrictive and less well deﬁned for functional or ischaemic MR [4]. The availability of
less invasive interventions is therefore the subject of growing interest and initial results
obtained using different percutaneous approaches have recently been reported.
Edge-to-edge technique
The percutaneous edge-to-edge technique reproduces the surgical technique described by
Dr Alﬁeri, which consists of a suture of the mid part of both mitral leaﬂets to create a
double mitral oriﬁce. The surgical technique has been used mainly in organic MR but cases
have also been performed in patients with functional MR [5].
The percutaneous edge-to-edge technique uses a transseptal approach to insert a
device, which aims to secure both leaﬂets. The technique currently used involves the
MitraClip (Abbott Inc.), in which a metallic clip is positioned at the free edge of the valve
and then closed to grasp both leaﬂets. The procedure is technically demanding, not only
because of the required expertise for transseptal catheterization, but also because of
the difﬁculties in catching the appropriate part of the leaﬂets under transoesophageal
echocardiography.
The MitraClip has been used in more than 2000 patients in the USA and in Europe, where
CE marking has been obtained this year. The most relevant evaluation of the MitraClip is
the Endovascular Valve Edge-to-Edge REpair Study (EVEREST) II randomized trial, which
was presented at the American College of Cardiology Meeting in 2010 but has not yet been
published. In this trial, 279 patients with severe MR were randomized in 37 centres to
MitraClip (n = 184) or surgical valve repair or replacement (n = 95). Mean age was 66 years
and 73% of the patients had organic MR. Procedural success was achieved in 74% of patients.
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intention-to-treat analysis showed a 30-day major adverse
vent rate of 15% in the MitraClip group and 48% in the surgi-
al group (p < 0.0001 for superiority). The superiority of the
itraClip can be partially explained by lower rates of atrial
brillation and, mainly, blood transfusions. The 12-month
linical success rate was 67% in the MitraClip group and 74%
n the surgical group (p = 0.0005 for non-inferiority). Accord-
ng to per-protocol analyses, i.e. considering patients who
ctually had an effective procedure, the 1-year residual rate
f MR grade greater than 2/4 was 18% in the MitraClip group
nd 3% in the surgical group. Respective 1-year rates of New
ork Heart Association (NYHA) class I or II were 98 vs. 88%
nd quality of life improved in both groups.
At present, published MitraClip experience is limited to
n observational series from the EVEREST registry involv-
ng 107 patients and two series from Germany and Italy
omprising, respectively, 51 and 31 patients [6—8]. These
eries differ particularly with regard to the aetiologies of
R, since the European series included a majority of patients
ith functional/ischaemic MR, whereas they accounted for
nly 21% of cases in the EVEREST registry. Patients from the
uropean series also had a higher risk proﬁle. Despite these
ifferences, these three series consistently showed high pro-
edural success rates, with a successful implantation of the
lip in greater or equal to 90% of patients and a ﬁnal MR less
r equal to two in at least three of four patients.
oronary sinus annuloplasty
he other percutaneous approach used to treat MR consists
f inserting a retractable device into the coronary sinus to
hrink the mitral annulus. The procedure reproduces the
rinciple of surgical valve repair in functional MR, which
onsists of a remodelling annuloplasty using an undersized
rosthetic ring. The rationale is the vicinity between the
oronary sinus and the mitral annulus, but there are also
imitations. Firstly, there is some distance between the coro-
ary sinus and the mitral annulus. Secondly, the coronary
inus corresponds only to approximately half of the circum-
erence of mitral annulus so that the annuloplasty is not
ircumferential, unlike with prosthetic rings. Finally, the cir-
umﬂex artery often crosses the coronary sinus and may be
ompromised by the retracting device.
At the present time, three devices have been tested in
umans:
the MONARCTM device (Edwards Lifesciences Inc.) consists
of a proximal and a distal stent connected by a bridge
that retracts progressively during the months following
implantation [9];
the CARILLONTM Mitral Contour System (Cardiac Dimen-
sions Inc.) device comprises a proximal and a distal nitinol
self-expandable anchor. The bridge connecting the two
anchors is positioned by manual traction under echocar-
diographic and ﬂuoroscopic control [10];
©the Viacor PTMA (PTMA Viacor Inc.) system is based on
a different approach and uses the implantation of several
nitinol rods through a multilumen catheter, enabling the
stiffness of the coronary sinus to be adjusted according to
the reduction of MR [11].
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Published experience in functional/ischaemic MR con-
erns 72 patients treated with the MONARCTM device, 48 with
he CARILLONTM device and 27 with the Viacor PTMA© device.
mplantation success rates vary between 48 and 82%, but
ncluded MR reduction in one series. Thirty-day death rates
re low, between 0 and 2%. The two main complications
re tamponade due to coronary sinus perforation, in 3—6%
f cases, and myocardial infarction in up to 6% of cases.
omplication rates are low for early feasibility trials but they
llustrate the speciﬁc risks of this approach. Compression of
he circumﬂex artery by the device, although seldom lead-
ng to myocardial infarction, is frequently observed when
sing a computed tomography scan during follow-up, in 30%
f patients with the MONARCTM device, resulting in coronary
tenosis greater than 50% in 8% [9].
Efﬁcacy has been evaluated in only small non-randomized
eries using surrogate endpoints. There was a decrease of at
east one grade of MR in 50% of patients at 1 year with the
ONARCTM device and in 22% of patients at 6 months with
he Viacor PTMA© device. Within the ﬁrst year, the effective
egurgitant oriﬁce area decreased by approximately 30% and
he regurgitant volume by 20—25%. The response was het-
rogeneous and certain patients experienced more marked
eductions of MR. Series analysing functional results within
he ﬁrst year reported an improvement in NYHA class and/or
-minute walk test [9,10].
otential impact of percutaneous
echniques in the treatment of mitral
egurgitation
lthough experience with percutaneous treatment of MR
s limited, there is evidence that different technical
pproaches are feasible. Procedural success rates are high
nd severe procedure-related complications are rare. It is
ikely that these ﬁgures will improve with growing experi-
nce and technical reﬁnements.
Feasibility does not, however, imply efﬁcacy, and it is too
arly to ascertain the clinical utility of these techniques. The
ecrease in MR severity is the most consistent ﬁnding and it
s obviously the ﬁrst goal when treating MR. The quantitation
f MR should combine different criteria including quantita-
ive measurements; their application to the MitraClip raises
roblems since no quantitative measurement is validated
or a double-oriﬁce. Results should be evaluated with longer
ollow-up since surgical experience has shown a higher rate
f late deterioration when the double-oriﬁce technique was
ot associated with annular remodelling [12]. Another pit-
all in the interpretation of MR severity in studies using the
itraClip is that they mix patients with organic MR with
hose with functional MR, although prognosis differs accord-
ng to thresholds of MR severity. In addition, functional MR
everity is subject to changes over time, particularly accord-
ng to loading conditions and/or treatment. The effect on
YHA class is a relevant endpoint but its assessment may be
ubjective.
Deﬁning indications for percutaneous techniques in the
reatment of MR will require separate analyses of organic
nd functional/ischaemic MR.
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The use of the MitraClip in organic MR should be com-
pared with the results of valve repair, which is frequently
feasible in the cases of valve prolapse selected in the EVER-
EST registry. Given the low operative risk and the good
immediate and late results of valve repair for valve pro-
lapse, it is unlikely that the MitraClip will replace surgery.
The rates of patients who still have at least moderate MR
after the Mitraclip procedure raise questions regarding long-
term beneﬁt. Nevertheless, percutaneous techniques are
attractive in patients with degenerative MR who are at
high surgical risk because of advanced age, comorbidities,
mitral annular calciﬁcation or prior aortic valve replace-
ment.
As regards functional/ischaemic MR, the situation is more
difﬁcult since, unlike in organic MR, surgery is not a refer-
ence treatment. Surgery carries a higher risk than in organic
MR, has not been shown to decrease mortality, and its effect
on symptoms varies across studies, in particular because of
the impact of confounding factors. It remains that the avail-
ability of low-risk interventions may be of potential interest
in these patients, who present an important population since
ischaemic MR has been shown to occur in as many as 50% of
patients after myocardial infarction and to have a negative
prognostic impact [13].
An accurate evaluation of existing techniques is needed
even more now that other procedures using transcatheter
approaches are under investigation, to be used individu-
ally or in combination: annuloplasty using radiofrequency,
chordal cutting, insertion of artiﬁcial chordae, etc. The
only application of an implantable prosthesis in mitral posi-
tion today is its use for valve-in-valve procedures in a
degenerated bioprosthesis [14]. Transcatheter implantation
of mitral prosthesis in a native valve is under consid-
eration but raises difﬁcult problems, in particular the
question of how to stabilize the prosthesis in the mitral
ring.
In conclusion, it is now likely that percutaneous
treatments will play a part in the treatment of MR.
Beyond early feasibility studies, randomized trials are
needed to control for confounders, particularly in func-
tional MR, since experience with surgery has shown
limitations of observational series in this setting. Con-
tinuous evaluation through large series and registries is
also mandatory to assess safety, not only because of
the need to assess larger numbers of patients but also
because application of the techniques will be expanded
beyond a limited number of expert centres. Large series
will also contribute to the identiﬁcation of patients
who are likely to derive a particular beneﬁt from the
procedure on the basis of objective and reproducible end-
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